[DOI] [PMC free article] [PubMed] [Google Scholar] 113.Marsico F, et al
Since each administrator handles documentation a little differently, a 60-second confirmation now could save you a headache down the road
In 2025, the company reported a solid +8.37% YoY revenue growth, led by key growth brands: Entresto ($7.74B) continues to expand in heart failure treatment, Cosentyx ($6.66B) maintains strong demand in immunology across multiple indications, and Kisqali ($4.78B) is rapidly gaining traction in breast cancer, supported by expanding clinical data and adoption
Making the Transition: A Step-by-Step Guide If you are currently on metformin and interested in starting a GLP-1 medication, following a structured process can help ensure your safety and success
Availability trumps theoretical superiority for most patients
The 39-amino-acid structure of retatrutide makes synthesis challenging